此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC (OHx-NOHx)

2016年5月10日 更新者:Prof. Shichun Lu、Chinese PLA General Hospital

Short- and Long-term Outcomes of Liver Resection With Versus Without Hepatic Inflow Occlusion for the Hepatitis B Virus-related Hepatocellular Carcinoma: a Prospective Randomized Controlled Trial

The study aims to compare the perioperative and long-term outcomes of liver resection for HBV-related HCC with versus without hepatic inflow occlusion.

研究概览

地位

未知

条件

详细说明

High prevalence of hepatitis B virus (HBV) imposes a huge burden of hepatocellular carcinoma (HCC) in Asia. Liver resection remains the mainstay of treatment for HCC. Hepatic inflow occlusion, known as the Pringle maneuver, is most commonly used to reduce blood loss during liver parenchymal transection. A major issue about this maneuver is the ischemia-reperfusion injury to the remnant liver. And the hemodynamic disturbance to the tumor-bearing liver remains an oncologic concern. Given the technical advances in living donor liver transplantation, vascular occlusion can be avoided in liver resection by experienced hands. This study aims to compare the perioperative and long-term outcomes of liver resection for HBV-related HCC without versus with hepatic inflow occlusion.

This study will include eligible patients with HBV-related HCC elected for liver resection. 57 patients will be enrolled in each randomized arm to detect a 20% difference in the serum level of total bilirubin on postoperative day 5 (80% power and α = 0.05). The secondary endpoints include procedural parameters, perioperative liver function and inflammatory response, postoperative morbidity and mortality, and long-term outcomes. Patients will be followed for up to five years. Data will be statistically analyzed on an intention-to-treat basis.

This prospective randomized controlled trial is designed to evaluate the feasibility of liver resections for HBV-related HCC without vascular occlusion. Clinical implication of its outcomes may change the present surgical practice and fill the oncologic gaps therein.

研究类型

介入性

注册 (预期的)

114

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing
      • Beijing、Beijing、中国、100853
        • 招聘中
        • Chinese PLA General Hospital
        • 接触:
        • 首席研究员:
          • Shichun Lu, M.D., Ph.D.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Elective liver resection due to HBV-related HCC with Barcelona-Clinic Liver Cancer (BCLC) staging 0 or A;
  2. Child-Pugh classified A with or without cirrhosis, or reversed to A from B after conventional therapy;
  3. Tumors located either in the left or right hemiliver;
  4. Resection extent was a hemi-hepatectomy or less;
  5. Informed consent.

Exclusion Criteria:

  1. Having comorbidity that contraindicates surgery;
  2. Participation in concurrent interventional trials with interference to this study;
  3. Eligible for laparoscopic hepatectomy;
  4. Requiring concomitant procedures, such as digestive, vascular or biliary reconstruction;
  5. Lack of compliance for treatment or future follow-up.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
无干预:Hx with hepatic inflow occlusion
Hepatectomy is carried out using Pringle maneuver in cycles of 15 minutes clamping + 5 minutes unclamping of the hepatoduodenal ligament.
实验性的:Hx with non-occlusion technique
Hepatectomy without hepatic inflow occlusion (non-occlusion technique)
Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
其他名称:
  • hepatectomy without hepatic inflow occlusion

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Serum total bilirubin on postoperative day 5
大体时间:5 days
Postoperative liver insufficiency characterized by the serum total bilirubin on POD 5.
5 days

次要结果测量

结果测量
措施说明
大体时间
Intraoperative blood loss
大体时间:Entire operation duration
Total blood loss from the incision to the closure of abdomen
Entire operation duration
Requirement of blood transfusion
大体时间:Entire operation duration
The amount of intraoperative blood transfusion
Entire operation duration
Operative time
大体时间:Entire operation duration
The time from induction of anesthesia to the closure of abdomen
Entire operation duration
Postoperative intensive-care unit (ICU) stay
大体时间:Duration of stay in ICU
Duration of stay in ICU
Duration of stay in ICU
Hospital stay
大体时间:Duration of hospital stay
Duration of hospital stay
Duration of hospital stay
Total hospital expenditure
大体时间:Duration of hospital stay
Total costs during hospital stay
Duration of hospital stay
Perioperative systemic inflammatory response
大体时间:an expected average of 7 days
Perioperative systemic inflammatory response is characterized by elevated serum level of tumor necrosis factor-α (TNF-α), interleukins (IL)-1α, 2, 6, 8 and 10, procalcitonin (PCT) and C-reactive protein (CRP) at different time points.
an expected average of 7 days
Postoperative morbi-mortality
大体时间:an expected average of 12 days in hospital
Postoperative morbi-mortality is characterized by postoperative complication and its severity based on Clavien-Dindo classification and in-hospital mortality
an expected average of 12 days in hospital
Long-term oncologic outcomes
大体时间:5 years after operation
1, 3, 5-year tumor recurrence rate
5 years after operation
Long-term survival
大体时间:5 years after operation
1, 3, 5-year overall survival (OS) and disease (tumor)-free survival (DFS)
5 years after operation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Shichun Lu, MD, PhD、Department of Hepatobiliary Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Haidian, Beijing, 100853, China

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2016年1月1日

初级完成 (预期的)

2019年1月1日

研究完成 (预期的)

2019年1月1日

研究注册日期

首次提交

2015年9月26日

首先提交符合 QC 标准的

2015年9月28日

首次发布 (估计)

2015年9月30日

研究记录更新

最后更新发布 (估计)

2016年5月12日

上次提交的符合 QC 标准的更新

2016年5月10日

最后验证

2016年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • JFJZYY-GD-15-01
  • NO. 2012BAI06B01 (其他赠款/资助编号:National Key Technology R&D Program of China)
  • NO. 2012ZX10002-017 (其他赠款/资助编号:National S&T Major Project for Infectious Diseases of China)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅